Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
about
Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.Cytotoxic mechanisms in vitro against Epstein-Barr virus infected lymphoblastoid cell lines in rheumatoid arthritisInterleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.The interleukin 2 gene is expressed in the syncytiotrophoblast of the human placenta.Lysis of primary hepatic tumours by lymphokine activated killer cellsLymphokine activated killer (LAK) cells in patients with gastrointestinal cancer.Therapeutic activity of NK cells against tumors.Enhancement of natural killer function through activation of the T11 E rosette receptorLymphocytes expressing type 3 complement receptors proliferate in response to interleukin 2 and are the precursors of lymphokine-activated killer cells.Anti-tumour efficacy of mouse spleen cells separated with Dolichos biflorus lectin (DBA) in experimental pulmonary metastasis of B16 melanoma cellsA cloned human T cell line cytotoxic for autologous and allogeneic B lymphoma cellsRegression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.Expression and rearrangement of the alpha, beta, and gamma chain genes of the T cell receptor in cloned murine large granular lymphocyte lines. No correlation with the cytotoxic spectrum.Lymphokine-activated killer cells. Analysis of progenitors and effectors.Studies of lymphokine-activated killer (LAK) cells. I. Evidence using novel monoclonal antibodies that most human LAK precursor cells share a common surface marker.Biologic response modifiers in gynecologic malignancies.Cytotoxic cellular mediators of the immune response to neoplasia: a review.Natural killer cell activation and interferon production by peripheral blood lymphocytes after exposure to bacteria.Lymphokine-activated-killer-mediated lysis of cells infected with typhus group rickettsiae can be inhibited by OKT3 monoclonal antibodyHuman natural killer cells, activated lymphocyte killer cells, and monocytes possess similar cytotoxic mechanisms.Photoaffinity labeling of ATP and NAD+ binding sites on recombinant human interleukin 2.Human interleukin 2: biochemistry, physiology, and possible pathogenetic role in immunodeficiency syndromes.Activation of lymphocyte anti-tumor responses in man. Towards an understanding of effector cell heterogeneity?Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.Human cytotoxic T lymphocytes evoked by group A streptococcal M proteins.Lymphokine-activated killer cells: biology and relevance to disease.Effects of heat shock on cytolysis mediated by NK cells, LAK cells, activated monocytes and TNFs alpha and beta.Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2.Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells.Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.Response of resting human peripheral blood natural killer cells to interleukin 2.Decreased natural killer (NK) susceptibility of human NK target cells after phosphatidylinositol-specific phospholipase C treatment.Immunoregulation of murine plasmacytoma. I. Generation of anomalous killer cells in vitro by cocultivation with MOPC 104E.Behaviorally conditioned modulation of natural killer cell activity: enhancement of baseline and activated natural killer cell activity.Defective immunological functions associated with abnormal lymphokine-activated killer activity in patients with hepatocellular carcinoma.Pregnancy is associated with a reduction in the pattern of the cytotoxic activity displayed by lymphokine-activated killer cells.Differential activation of lymphokine-activated killer cells with different surface phenotypes by cultivation with recombinant interleukin 2 or T-cell growth factor in gastric cancer patients.Generation and characterization of lymphokine-activated killer cells against fresh human leukemia cells.Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.Antitumor activity and its properties of Eubacterium lentum.
P2860
Q24548127-74D36A4B-112B-4673-B61D-80CD30024165Q33556764-EE4E59C3-2789-4C5B-B66A-566B3A60DF96Q33821969-D71A2187-66A6-431C-A1AC-3F959C2305C1Q33832658-A56EBC03-3AEE-4563-8807-C7993674AB81Q34527814-FF53F415-7500-42CE-A42C-3FF5B56425DEQ34530255-AAF65AE0-F7C5-481A-B4A7-2CA5D1A5F20EQ34552162-F58265ED-2A70-4F63-9645-9858E6145D5DQ34556806-3AC100BB-88AC-40BB-9593-69C27B00BFFBQ35811833-9026C47A-8EAA-438D-B16E-C12EB87583DDQ35981853-8713EC81-44C9-4A8B-B430-124DB1ADA7A7Q36349234-12841371-704F-482A-8B8B-DC341F53C9FBQ36350050-867B91B2-02AE-4B2A-928B-73923FA9A63DQ36352253-83B61575-7214-4E6B-9AE3-F5F877E77D8DQ36352956-A0C24CEE-7280-46FB-AEB3-BF1BFA54E07FQ36356148-28FE584E-24B9-4124-B2F9-AB2344381B14Q36989437-18177B0B-C7CF-4B72-B523-0FE239474AF6Q36989528-F45CE5C1-7BD7-4E29-9D84-934F7CBEDD58Q36996539-2BF1DFFF-6CC6-4514-B259-083C000AEA5BQ37011658-EADA7015-615C-4052-8B92-53B778F3219BQ37690860-FBF7D0B0-F7F0-4EE2-B641-E0E3363E081DQ37691763-BD1C089A-7661-42A4-B22C-8B986F4020C9Q39845943-3BCECBB2-2D15-4B55-BC91-6FABA9854325Q40117876-435E588F-55D4-4843-B2CB-AB9E6D447343Q40790546-6AD22163-458A-4F2C-9BE6-5C647245C265Q40792016-B8711158-B5A6-4163-94B3-CBFB9BF7DBA4Q40822463-EFBA06AB-01FB-4B41-88DE-A986961BD026Q41224733-421ABC79-0668-4DBD-8278-049A1189112EQ41661156-AFB1C46E-8397-4174-99CE-443F80CFDA0CQ41844970-F2CADBEC-84FA-4F7F-A9FB-D9D5D2643478Q42041842-2837C81F-71C4-4848-B30B-7361CD7D3D78Q42153962-D2389132-1DC1-4FAB-A2D8-7252DDAAB513Q43554304-E45A1A22-EC23-46CE-85FE-CD8DBBFBFBC1Q43561202-82EDFC0B-0668-41E7-8AD1-5B362BEE30F8Q44719428-E27D6D75-7F9D-40AC-B7D4-558F122DCB80Q46879840-91D6A23F-23A4-4F60-9DCC-D8F035E99FF1Q54283250-9FA528A2-5836-4108-A6B6-3320E9E00B72Q54361413-FF5CA7EE-9697-4E22-8BFB-BE4F9457EB37Q54388045-6A731F3F-1FE2-4855-9995-6D8BA2E845E8Q54963796-A73BC43B-A1F7-4EEF-8B1F-16776C419E59Q55019574-994C31C2-6063-4CA1-BDF2-2A599C6EDBFB
P2860
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh
1983年學術文章
@zh-hant
name
Lymphokine-activated killer ce ...... tes, and natural killer cells.
@ast
Lymphokine-activated killer ce ...... tes, and natural killer cells.
@en
type
label
Lymphokine-activated killer ce ...... tes, and natural killer cells.
@ast
Lymphokine-activated killer ce ...... tes, and natural killer cells.
@en
prefLabel
Lymphokine-activated killer ce ...... tes, and natural killer cells.
@ast
Lymphokine-activated killer ce ...... tes, and natural killer cells.
@en
P2093
P2860
P356
P1476
Lymphokine-activated killer ce ...... tes, and natural killer cells.
@en
P2093
P2860
P304
P356
10.1084/JEM.157.3.884
P407
P577
1983-03-01T00:00:00Z